NICE recommends SCS for spine pain management
The National Institute for Health and Clinical Excellence has issued a guidance which recommends the availability of Spinal Cord Stimulation (SCS) to all patients suffering from chronic neurologic pain for a minimum of 6 months after note benefiting from conventional treatment for pain management. Before implantation, the patients would go through a trial of the treatment. The guidance is a ray of hope for patients with Failed Back Surgery Syndrome (FBSS). In this therapy, electric pulses are sent to electrodes attached to a fully implanted neurostimulator battery. They interrupt the pain messages sent to the brain.

The U.S. Food and Drug Administration has cleared US Spine’s Preference 2 Complex Spine System™ for use in the United States. With this approval, 
The European Commission has granted orphan drug designation to Cethrin developed by 
Surgeons are using custom-made, FDA-approved device, STARband, to begin the cranial shaping process of children below 18 months of age diagnosed with craniosynostosis. Craniosynostosis is a condition that leads to premature fusion of the cranial sutures, or fontanels, causing problems with normal brain and skull growth, which can result in developmental delays, visual impairment and misaligned ears, eyes, and jaws.